Exact Sciences Shareholders Approve Abbott Merger, Reject Executive Pay Plan
Exact Sciences stockholders approved the planned merger with Abbott at a special meeting on February 23 after securing the required majority vote. Simultaneously, the proposal for the company’s executive compensation package failed to reach approval, indicating investor resistance to management pay terms.
1. Special Meeting Results
On February 23, Exact Sciences convened a special shareholder meeting where proposals on the Abbott merger and executive compensation were presented to investors.
2. Merger Approval
Shareholders voted in favor of the merger agreement with Abbott Laboratories, surpassing the required majority threshold to combine operations and pursue joint diagnostic and screening initiatives.
3. Executive Compensation Vote
The proposal outlining the executive pay package did not receive sufficient support, falling short of the approval threshold and signaling shareholder concerns over management remuneration.
4. Next Steps
Approval of the merger clears a key governance hurdle, allowing the companies to proceed with closing, while the failed pay plan is expected to be revised and resubmitted to investors for approval.